{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:31:17Z","timestamp":1736400677475,"version":"3.32.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.09.022","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:21:05Z","timestamp":1729509665000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness Analysis of Tumor Treating Fields Therapy Combined With Immune Checkpoint Inhibitor in Metastatic Non-small-cell Lung Cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Mengwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-1017","authenticated-orcid":false,"given":"Ping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-3323","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.022_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0003","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.22.02121","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline, version 2022.2","volume":"41","author":"Owen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.25259\/SNI_674_2023","article-title":"Tumor treating fields for the treatment of glioblastoma: current understanding and future perspectives","volume":"14","author":"Colamaria","year":"2023","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0006","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0007","article-title":"Effectiveness and safety of tumor-treating fields therapy for glioblastoma: a single-center study in a Chinese cohort","volume":"13","author":"She","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0008","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0009","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9343(82)90786-0","article-title":"A convenient approximation of life expectancy (the \"DEALE\"). I. Validation of the method","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0011","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0002-9343(82)90787-2","article-title":"A convenient approximation of life expectancy (the \"DEALE\"). II. Use in medical decision-making","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.oraloncology.2017.09.017","article-title":"Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer\u2606","volume":"74","author":"Ward","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0013","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s41669-020-00245-4","article-title":"Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England","volume":"5","author":"Rothwell","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0014","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11096-020-01076-3","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer","volume":"42","author":"Lin","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0016","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0017","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.21037\/tlcr-23-469","article-title":"First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis","volume":"12","author":"Liu","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0018","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0019","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M22-1258","article-title":"Anticoagulant therapy for cancer-associated thrombosis: a cost-effectiveness analysis","volume":"176","author":"Gulati","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0021","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer","volume":"19","author":"Ding","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2023.70012","article-title":"Cost-effectiveness analyses in AML: what have we learned, how should this impact patient care, and what needs to be done in the future","volume":"21","author":"Bewersdorf","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","article-title":"Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"21","author":"Mehrens","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0024","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1007\/s12325-023-02594-y","article-title":"The cost-effectiveness of sugemalimab plus chemotherapy as first-line treatment for metastatic squamous and non-squamous NSCLC in China","volume":"40","author":"Cheng","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-020-03563-z","article-title":"A systematic review of tumor treating fields therapy for high-grade gliomas","volume":"148","author":"Shah","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0026","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/neuonc\/now102","article-title":"The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma","volume":"18","author":"Bernard-Arnoux","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ctrv.2018.02.005","article-title":"Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC","volume":"65","author":"Melosky","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2024.09.022_bib0028","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(23)00394-7","article-title":"Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer","volume":"24","author":"Fennell","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:57:02Z","timestamp":1736366222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0149291824002856"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analysis of Tumor Treating Fields Therapy Combined With Immune Checkpoint Inhibitor in Metastatic Non-small-cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}